Interesting piece in the August Life Extension magazine.
Beta blockers inhibit progression in liver, breast, ovarian, pancreatic & colon cancer. Melanoma too, but conspicuously absent from the LEF list is PCa.
A few weeks ago, there was a PCa meta-analysis [1]:
"Ten studies met our inclusion criteria and a total of 74,970 patients were included: 26,674 beta-blocker users and 48,326 nonusers. There was no statistically significant association between beta-blocker exposure and PCa mortality".
Perhaps someone might offer a possible explanation?
The LEF article cited a 2021 meta-analysis for early-stage breast cancer [2]:
"In this meta-analysis, beta-blocker use was associated with a longer {recurrence-free survival} in patients with early-stage breast cancer, with a more pronounced effect observed in those with triple-negative disease."
However, no citation for general BCa. Cherry-picking?
-Patrick